Pfizer announces results from XELJANZ XR ORAL Shift study
Patients who achieved low disease activity (LDA) with XELJANZ (tofacitinib) extended release (XR) 11 mg once daily (QD) plus methotrexate (MTX) after a 24-week open-label run-in period, were
France-based biopharmaceutical company Osivax has entered into an exclusive license option agreement with Japanese vaccine manufacturer KM Biologics for a broad-spectrum “universal” influenza vaccine candidates in Japan.
PhoreMost has identified and validated the target using its next-generation SITESEEKER phenotypic screening technology. Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors
Cosentyx is claimed to be the first and only fully-human biologic, which directly restricts interleukin-17A (IL-17A), a cornerstone cytokine engaged in the inflammation and development of PsA, psoriasis
Having established their collaboration in the 1980s, this extension represents a long-term commitment to patients, offering the benefits of Decapeptyl in the treatment of metastatic and non-metastatic patients
The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments. Both